These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22114896)

  • 21. Cost-utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort.
    Forster R; Ratcliffe A; Lewis M; Crossley A; Bastida JL; Dunlop WCN
    Eur J Health Econ; 2018 Dec; 19(9):1303-1318. PubMed ID: 29754324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD; Buxton M; Andersson LF; Lamm CJ; Liljas B; Chen YZ; Pauwels RA; Weiss KB
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
    Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.
    FitzGerald JM; Arnetorp S; Smare C; Gibson D; Coulton K; Hounsell K; Golam S; Sadatsafavi M
    Respir Med; 2020 Sep; 171():106079. PubMed ID: 32917353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    J Asthma; 2016 Jun; 53(5):538-45. PubMed ID: 26786524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Internet-based self-management plus education compared with usual care in asthma: a randomized trial.
    van der Meer V; Bakker MJ; van den Hout WB; Rabe KF; Sterk PJ; Kievit J; Assendelft WJ; Sont JK;
    Ann Intern Med; 2009 Jul; 151(2):110-20. PubMed ID: 19620163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
    Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
    Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
    J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients.
    Manfrin A; Tinelli M; Thomas T; Krska J
    BMC Health Serv Res; 2017 Apr; 17(1):300. PubMed ID: 28438152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST.
    McKeever T; Mortimer K; Bradshaw L; Haydock R; Pavord I; Higgins B; Walker S; Wilson A; Price D; Thomas M; Devereux G; Brightling C; Renwick C; Parrott S; Mitchell E; Duley L; Harrison T
    Health Technol Assess; 2018 Dec; 22(70):1-82. PubMed ID: 30520413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
    Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
    Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
    J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 36. Preferences and utilities for the symptoms of moderate to severe allergic asthma.
    Lloyd A; Doyle S; Dewilde S; Turk F
    Eur J Health Econ; 2008 Aug; 9(3):275-84. PubMed ID: 18038166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial.
    Vasbinder EC; Goossens LM; Rutten-van Mölken MP; de Winter BC; van Dijk L; Vulto AG; Blankman EI; Dahhan N; Veenstra-van Schie MT; Versteegh FG; Wolf BH; Janssens HM; van den Bemt PM
    Eur Respir J; 2016 Sep; 48(3):758-67. PubMed ID: 27230437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab for the treatment of severe persistent allergic asthma.
    Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
    Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.